Rhabdomyolysis, a syndrome of muscle necrosis, is a life-threatening event. Here we describe the case of a patient with chronic myeloid leukemia who underwent a haploidentical stem cell transplant and subsequently developed rhabdomyolysis after beginning trimethoprim-sulfamethoxazole (TMP/SMX) prophylaxis therapy. Rechallenge with TMP/SMX resulted in a repeat episode of rhabdomyolysis and confirmed the association. Withdrawal of TMP/SMX led to sustained normalization of creatine kinase levels in the patient. A high index of suspicion is necessary to identify TMP/SMX as the cause of rhabdomyolysis in immunocompromised patients.
Download full-text PDF |
Source |
|---|---|
| http://www.ncbi.nlm.nih.gov/pmc/articles/PMC4628682 | PMC |
| http://dx.doi.org/10.1155/2015/619473 | DOI Listing |
Publication Analysis
Top Keywords
rhabdomyolysis trimethoprim-sulfamethoxazole
8
stem cell
8
cell transplant
8
rhabdomyolysis
5
trimethoprim-sulfamethoxazole administration
4
administration hematopoietic
4
hematopoietic stem
4
transplant rhabdomyolysis
4
rhabdomyolysis syndrome
4
syndrome muscle
4
Similar Publications
Want AI Summaries of new PubMed Abstracts delivered to your In-box?
Enter search terms and have AI summaries delivered each week - change queries or unsubscribe any time!